Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte.
Jin J., Shi Y., Gong J., Zhao L., Li Y., He Q.
Animal Study on Type 1 Diabetes, Type 2 Diabetes, Chronic Kidney Disease, published in Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cell Res Ther (2019)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 30876481
- PMCID
- PMC6419838
- DOI
- 10.1186/s13287-019-1177-1
- Citations
- 296
Abstract (original English)
Background It is confirmed that adipose-derived stem cells (ADSCs) transplantation effectively relieves kidney fibrosis and type 2 diabetes disease in mice. Currently, exosome from urine-derived stem cells (USCs) can protect type 1 diabetes-mediated kidney injury and attenuate podocyte damage in diabetic nephropathy (DN). Exosome derived from USCs has evolved into the strategy for DN treatment, but the role of ADSCs-derived exosome (ADSCs-Exo) in DN remains unclear. The present study is aimed to investigate the therapeutic action and molecular mechanism of ADSCs-derived exosome on DN. Methods ADSCs and exosome were authenticated by immunofluorescence and flow cytometry. Morphology and the number of exosome were evaluated by electron microscope and Nanosight Tracking Analysis (NTA), respectively. Cell apoptosis was assessed using flow cytometry. Podocyte autophagy and signaling transduction were measured by immunofluorescence and immunoblotting. Dual Luciferase Reporter assay was employed to detect the regulatory relationship between miR-486 and Smad1. Results ADSCs-Exo attenuated spontaneous diabetes by reducing levels of urine protein, serum creatinine (Scr), blood urea nitrogen (BUN), and podocyte apoptosis in mice. In in vitro experiment, ADSCs-Exo also reversed high glucose-induced decrease of cell viability and the increase of cell apoptosis in MPC5 cells. In terms of mech
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Transforming hypoglycemia prediction in adult type 1 diabetes: a systematic review and meta-analysis for precision care
Meta-analysis on Type 1 Diabetes, published in Open Life Sci (2026) — summary generated from the PubMed abstract.
- 2026
Open Life Sci - Level ASystematic ReviewEurope PMC
Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review
Systematic Review on Type 1 Diabetes, published in Front Transplant (2025) — summary generated from the PubMed abstract.
- 2025
Front Transplant - Level AMeta-analysisEurope PMC
Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis
Meta-analysis on Type 1 Diabetes, published in J Diabetes Res (2020) — summary generated from the PubMed abstract.
- 2020
J Diabetes Res7 citations - Level AMeta-analysisEurope PMC
Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits
Meta-analysis on Type 1 Diabetes, Type 2 Diabetes, published in Stem Cell Investig (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cell Investig22 citations - Level AMeta-analysisEurope PMC
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis
Meta-analysis with a reported sample of 524 on Type 1 Diabetes, published in PLoS One (2016) — summary generated from the PubMed abstract.
- 2016
- n = 524
PLoS One81 citations - Level BClinical TrialEurope PMC
Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Clinical Trial on Type 1 Diabetes, Type 2 Diabetes, Scar, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells1 citations